У нас вы можете посмотреть бесплатно Da Vinci Single Port Surgical Robot - Dr Richard Gallagher, ENT Surgeon, Sydney. World Cancer Day или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Hosted by Julie McCrossin AM Head & Neck Cancer Patient Advocate Thank you Dr Richard Gallagher, ENT Surgeon St Vincent's Hospital Sydney The Kinghorn Cancer Centre Media production Daniel Taylor Thank you Cancer Voice SA cancervoicessa.org.au 1. The Innovation: Da Vinci Single Port (SP) Robot The Technology: Unlike the traditional "multi-port" robot used since 2011, which utilized multiple large arms , the new Single Port (SP) system uses one 10cm entry port. Capabilities: This single port contains four smaller, flexible instruments, including a 3D camera. The Benefit: These instruments allow for higher precision and the ability to expand and work within the very tight spaces of the throat. 2. Clinical Impact on Patient Care Expanded Eligibility: The SP robot may provide access for patients who were previously ineligible for robotic surgery due to limited mouth opening. Deeper Reach: It allows for safer, more accurate surgery further down the throat, specifically in areas like the hypopharynx and around the voice box. Reduced Trauma: Dr. Gallagher contrasts this with "heroic" older operations that required splitting the jawbone, tracheotomies, and weeks of hospital recovery. Availability: In Australia, this technology is currently available at St Vincent’s in Sydney and the Epworth Hospital in Melbourne. 3. Public Health: The HPV Crisis The Cause: The Human Papillomavirus (HPV) is a sexually transmitted virus that is now the primary driver of rising oropharyngeal cancer rates, even as smoking and drinking rates have declined. Incidence: Despite the success of the Australian-developed vaccine, rates in older cohorts (who were not vaccinated in school) continue to increase.